Three-year data from Oraya Therapeutics’ INTREPID study continue to show favorable safety profile of non-invasive wet AMD therapy
Oraya Therapeutics Inc. has announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further...